Intravitreal Ranibizumab in Daily Clinical Practice for Age-Related Macular Degeneration: Treatment of Exudative Age-Related Macular Degeneration in Real Life

Publisher： Karger

E-ISSN： 1423-0267|234|1|26-32

ISSN： 0030-3755

Source： Ophthalmologica, Vol.234, Iss.1, 2015-06, pp. : 26-32

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Treatment of Exudative Age-Related Macular Degeneration with Intravitreal Ranibizumab in Clinical Practice: A 3-Year Follow-Up

By  

Ophthalmologica, Vol. 229, Iss. 3, 2013-03 ,pp. : 158-167

Karger

Access to resources Recommend Favorite

A Review of Ranibizumab Clinical Trial Data in Exudative Age-Related Macular Degeneration and How to Translate It into Daily Practice

By  

Ophthalmologica, Vol. 225, Iss. 2, 2010-10 ,pp. : 112-119

Karger

Access to resources Recommend Favorite

Switch from Intravitreal Ranibizumab to Bevacizumab for the Treatment of Neovascular Age-Related Macular Degeneration: Clinical Comparison

By  

Ophthalmologica, Vol. 232, Iss. 3, 2014-08 ,pp. : 149-155

Karger

Access to resources Recommend Favorite

Intravitreal Ranibizumab and Bevacizumab in Combination with Full-Fluence Verteporfin Therapy and Dexamethasone for Exudative Age-Related Macular Degeneration

By  

Ophthalmic Research, Vol. 45, Iss. 3, 2010-09 ,pp. : 129-134

Karger

Access to resources Recommend Favorite

The Effect of Intravitreal Ranibizumab on the Fellow Untreated Eye with Subfoveal Scarring due to Exudative Age-Related Macular Degeneration

By  

Ophthalmologica, Vol. 223, Iss. 6, 2009-07 ,pp. : 383-389

Karger

Access to resources Recommend Favorite